Every year, MedGadget publishes the Medical Blog Awards.
And here’s last year’s winners.

HealthNewsReview - Best Medical Weblog of 2009	SCOPE - Best New Medical Weblog
StorytellERdoc - Best Literary Medical Weblog	Life in The Fast Lane - Best Clinical Weblog
ACP Advocacy Blog - Best Health Policies/Ethics Weblog	ScienceRoll - Best Medical Technologies/Informatics
Wheelchair Kamikaze - Best Patient's Blog
Congratulations to all the winners! Full story on MedGadget Link: 2009 Medical Weblog Awards announcement…

Did you know you can search for ads by company name, brand or even generic name on AdPharm?

Here’s just a few as an example:

• Company: Pfizer, Merck, Sanofi, Novartis, Aventis, Boiron, Schering…
• Brand name: Lipitor, Avapro, Boniva, Cymbalta, Aspirin, Zyrtec…
• Generic name: sildenafil, insulin, drospirenone, varenicline…

Use the search page or simply type your keywords in the quick search filed that appears on the top right portion on all of the pages on the site. You can also have a look at our Sections page, where ads are categorized using various keyword groupings.

Thousands of pharmaceutical ads can be seen on the AdPharm gallery, the largest keyword-searchable online pharmaceutical advertising gallery.

Mind the Gap is a new blog from Steve Wilkins gathering information and thoughts about communication between physicians and their patients… or lack thereof.

In his own words:

“Mind the Gap”  is a warning heard on subway systems around the world.  It is intended to alert individuals to avoid accidentally stepping in the “gap” that separates the train from the platform.

As used here, it is an expression that alludes to the communications gap that exists all too often today between patients and their physicians.   Like the subway, this blog is a kind of warning.  It is intended to making health care provider and organizations aware of the consequences of poor physician-patient communications…and how to avoid them.

Have a look at Mind the Gap. We’re sure there will be some nice informative gems in there that will trigger ideas on how big pharma or biotechs and their agencies can help HCPs better communicate with patients.

Microsite

Prilosec.
Official sponsor or everything you do without heartburn

Description: This Social Marketing effort is meant to bring people the the Prilosec sponsor site and get them to enlist to be sponsored. In their own words: “Tell us who you are, what you love to do, and what you need to do it better. We also want to know, if sponsored, who you would tell about it.”

Once people have applied for sponsorship, their application becomes live on the site and people can vote for them. Throughout this, visitors are exposed to Prilosec and its benefits.

The winners get a gift in line with their passion.

With the campaign, there is a microsite, an official blog, a Twitter page and a Facebook page.

Brand name: Prilosec
Generic name/category: Omeprazole, Proton pump inhibitors (PPI)
Company: AstraZeneca and Proctor & Gamble
Country/Market: USA, North America
Indication(s)/use: dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome
Target: Direct-to-consumers (DTC)
Tagline: Heartburn gone. Power on.
Medium: Social Media
Size/duration: Microsite, official blog, Twitter page and Facebook page.
Publication/Aired: 2010

To see all of this brand’s ads on AdPharm, click here

These ads and thousands more can be seen on the AdPharm gallery, the largest keyword searchable online pharmaceutical advertising gallery.

3M just launched a brand new online Visual Attention service which analyzes images and tells you how viewers will look at your image, or advertisement and in which sequence. And this is based on 30 years of vision science research.

Some of the views you have access to when on the site

Read the rest of this entry »

The Pharmageddon viral and social marketing effort portraying the end of the pharmaceutical marketing as we know has been officially claimed. S+R Medical Communications and Friday Morning have finally released this video on YouTube admitting to everything.

Phamaceutical marketing as we know it is not as viable as it once was. Something needs to change and S+R and Friday morning, after conducting market research decided to do something about it with this innovative campaign.

Does it mean it’s all finished? No more zombie-reps going after doctors for their prescriptions? The countdown on the Pharmageddon microsite is still going, so maybe they have a few more surprises in their bag…

See the Pharmageddon album on AdPharm where you can find all links related to the campaign.

Related posts on blog.adpharm.net:

• Pharmageddon 2012 – the end of an era for pharmaceutical marketing?
• Who is behind Pharmageddon 2012?

Learn about high cholesterol and plaque buildup. Take an interactive artery tour.

Description: This is a very elaborate site on the risks associated with high cholesterol and plaque buildup. It also is a comprehensive sales-pitch for Crestor. Whats new about this Crestor site is that it uses a form of augmented reality to educate people about high cholesterol and plaque buildup.

Click here to visit the site.

To see all of the ads from this campaign, click here

Brand name: Crestor
Generic name/category: Rosuvastatin, statins
Company: AstraZeneca
Country/Market: USA, North America
Indication(s)/use: high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia)
Target: Consumer (DTC)
Medium: Internet
Publication: 2009

To see all Crestor ads, click here

From Wikipedia:
Rosuvastatin is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. Shionogi developed the product and the pharmaceutical company AstraZeneca markets it as Crestor.

Rosuvastatin is approved for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia).

As of 2004, rosuvastatin had been approved in 154 countries and launched in 56. Approval in the United States by the FDA came on August 12, 2003.

More on Wikipedia

Click here to see the details and full-size version of this ad on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.